Since 2008, Cure ATRT Now, has been funding ATRT targeted research at Dana Farber & St Jude’s hospital. This inspiring story is the reason we continue doing w...

We continue to fight to find a cure for ATRT. This is a long & complicated fight but we are making progress, albeit slowly. This is the research that you & a...

Epizyme announces first patient dosed in global clinical program. Dana Farber Cancer Institute and Cincinnati Children's Hospital are the first sites activat...

New research posted to the We Can Help -> Research section of the web site. Pitfalls in Diagnosing AT/RT: Experiences From the European Rhabdoid Tumor Regist...

This presentation contains a lot of information, much of it very technical. The study is not specific to AT/RT, but does include AT/RT patients and could off...

Epizyme, Inc. a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today announced the U.S. Food and Drug...

For those just learning about AT/RT, here is an helpful post from the Dana Farber Cancer Institute: http://blog.dana-farber.org/insight/2015/08/what-is-atrt-...

Barcelona, Spain, November 20, 2014 – Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics ...